The efficacy of
photodynamic therapy (
PDT) in some solid
tumors is limited by the poor biodistributive properties of conventional
photosensitizers and a natural predisposition of
tumor cells to survive
hypoxia and oxidative stress. This study investigated the therapeutic potential of a third-generation
photosensitizer, liposomal
zinc phthalocyanine (ZnPC), in combination with the hypoxic
cytotoxin tirapazamine (TPZ). TPZ induces
DNA double strand breaks (DSBs) under hypoxic conditions and subsequent apoptosis via p53 signaling. Experiments were performed in
tumor cells with functional p53 (Sk-Cha1) and dysfunctional p53 (A431). The combination
therapy of TPZ and
PDT induced
DNA DSBs and cell cycle stalling and enhanced the cytotoxicity of
PDT by exacerbating apopotic and non-apoptotic
tumor cell death. These phenomena occurred regardless of
oxygen tension and the mechanism of cell death differed per cell line.
Liposomes containing both ZnPC and TPZ exhibited no dark toxicity but were more lethal to both cell types after
PDT compared to ZnPC-
liposomes lacking TPZ—an effect that was more pronounced under hypoxic conditions. In conclusion, TPZ is a suitable pharmaceutical compound to increase
PDT efficacy by exploiting the post-
PDT tumor hypoxia. The inclusion of TPZ and ZnPC into a single liposomal delivery system was feasible. The
PDT strategy described in this study may be valuable for the treatment of
PDT-recalcitrant
tumors.